Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.
Joseph Maakaron, MD
Advertisement
Articles by Joseph Maakaron, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
5